Ruohan Diao, Xingwu Duan, Lingling L I, Tiange Q U, Huishang Feng, Guangshan Chen
Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Beijing University of Chinese Medicine, Beijing 100029, China.
J Tradit Chin Med. 2025 Jun;45(3):552-560. doi: 10.19852/j.cnki.jtcm.2025.03.004.
To explore the therapeutic mechanisms of Xiaoyin Anshen Yin (, XYAS) in treating psoriasis associated with sleep focusing on melatonin and the regulation of the nuclear factor kappa-B (NF-κB) pathway.
Forty Sprague-Dawley rats were randomly divided into four groups, and administered distilled water, XYAS and its two different disassembly prescriptions by gavage respectively. Four types of drug-containing serums corresponding to the four groups were then prepared. Tumor necrosis factor (TNF)-α stimulated HaCaT was used to establish a psoriasis cell model, and the serums and the retinoid related orphan receptor alpha (RORα) inverse agonist were used respectively to intervene in the model. Enzyme-linked immunosorbent assay was used to detect the levels of interleukin (IL)-6 and melatonin in each group; flow cytometry was used to detect the levels of reactive oxygen species (ROS), mitochondrial membrane potential, and apoptosis; Western blot was used to evaluate the levels of superoxide dismutase 2 (SOD2), cytochrome-c (Cyt-c), inhibitor of kappa-B alpha (IκBα), p65 and phosphorylated p65.
XYAS and its disassembly prescriptions inhibited the secretion of inflammatory factors such as IL-6, reduced the ROS content and Cyt-c expression, increased the mitochondrial membrane potential and SOD2 content, promoted the apoptosis in HaCaT cells and inhibited the activation of the NF-κB pathway. XYAS was also found increase the melatonin content. The above effects are beneficial in the treatment of psoriasis combined with sleep disorders. Meanwhile, XYAS no longer had a significant ameliorative effect after applying the RORα inverse agonist, suggesting that the therapeutic effect of XYAS is related to RORα.
The results of this study confirm that XYAS can be utilized for the treatment of psoriasis combined with sleep disorders inhibiting the NF-κB pathway, anti-inflammatory, antioxidant and pro-apoptotic, which is in part related to the regulatory role of melatonin and its receptor RORα.
探讨消银安神饮（XYAS）治疗伴睡眠障碍银屑病的作用机制，重点关注褪黑素及核因子κB（NF-κB）通路的调控。
将40只Sprague-Dawley大鼠随机分为四组，分别通过灌胃给予蒸馏水、XYAS及其两种不同拆方制剂。然后制备对应四组的四种含药血清。用肿瘤坏死因子（TNF）-α刺激HaCaT细胞建立银屑病细胞模型，分别用血清及视黄酸相关孤儿受体α（RORα）反向激动剂干预该模型。采用酶联免疫吸附测定法检测各组白细胞介素（IL）-6和褪黑素水平；采用流式细胞术检测活性氧（ROS）水平、线粒体膜电位及细胞凋亡情况；采用蛋白质免疫印迹法评估超氧化物歧化酶2（SOD2）、细胞色素c（Cyt-c）、κB抑制蛋白α（IκBα）、p65及磷酸化p65的水平。
XYAS及其拆方制剂可抑制IL-6等炎性因子分泌，降低ROS含量及Cyt-c表达，增加线粒体膜电位及SOD2含量，促进HaCaT细胞凋亡并抑制NF-κB通路激活。还发现XYAS可增加褪黑素含量。上述作用均有利于伴睡眠障碍银屑病的治疗。同时，应用RORα反向激动剂后XYAS不再有显著改善作用，提示XYAS的治疗作用与RORα有关。
本研究结果证实，XYAS可用于治疗伴睡眠障碍的银屑病，其作用机制为抑制NF-κB通路、抗炎、抗氧化及促凋亡，部分与褪黑素及其受体RORα的调节作用有关。
